Rockwell Medical Technologies, Inc. Receives Nasdaq Staff Determination

Business Wire, May 15, 2001

Business Editors & Health/Medical Writers

WIXOM, Mich.--(BUSINESS WIRE)--May 15, 2001

Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, said today that it received a Nasdaq Staff Determination on May 8, 2001, that the Company does not comply with the $1.00 minimum bid price requirements set forth in Marketplace Rule 4310(c)(4) and that its securities are subject to delisting from the Nasdaq SmallCap Market.

The Company has requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff Determination. Until the Panel reaches its decision, the Company's stock will remain listed and will continue to trade on the Nasdaq SmallCap Market. There can be no assurance the panel will grant the Company's request for continued listing.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte(TM) Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Visit Rockwell's website at www.rockwellmed.com for more information.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.